Makers of a glaucoma drug that has also been used as a key ingredient in cosmetic treatments to make eyelashes longer have announced plans for a new trial into its potential use combating hair loss from Male Pattern Baldness.
Allergan, which has headquarters in Dublin and New Jersey, hope to recruit 90 people with male pattern hair loss for a one-year study into what effect their drug Bimatoprost has on their scalps. They will be using different concentrations and formulations of the drug on different subjects and state that their objectives are to measure adverse effects, its tolerability and its effects on plasma levels. It seems that there will be no study into the efficacy of the drug as a possible hair loss medication during this specific trial.
Previous clinical trial delayed
It is not the first time that Allergan has conducted clinical trials into the use of its drugs on people with hair loss: an a mid-stage trial report suggested it had failed to demonstrate sufficient efficacy to proceed to a late stage study.
The news at the time was met with some disappointment across the hair loss industry, as initial laboratory research into the product suggested it showed promise as a possible future treatment for MPB. When tested on living scalp tissues, follicles that were treated grew by a third more than untreated tissue in nine days.
The new trial will shortly be looking for test subjects with mild to moderate MPB with ongoing hairloss for at least a year. The company further state that participants should be between 18 and 49 years, and that anyone who currently applies topical applications of the medically-proven hair loss medication minoxidil needs to have stopped using it at least four weeks before the trial starts.
Minoxidil for hair loss
Whilst bimatoprost is still in development, there are of course other effective hair loss treatment options available now for men currently concerned about their thinning hair.
Minoxidil is one of only two clinically-proven medications for androgenic alopecia that people typically turn to when their hair starts to thin. It started life as an oral drug to treat high blood pressure; a topical version specifically for the scalp was later developed after patients noticed that the drug made their hair thicker.
How it works is the subject of some debate: many believe that the drug dilates the blood vessels around the hair follicles, which increases the flow of nutrients (and oxygen-carrying blood) to the scalp. Others believe that Minoxidil opens up potassium channels in the scalp, and that this also leads to hair growth.
The range of high strength minoxidil products offered by Belgravia have resulted in large numbers of success stories – like the one pictured here – and has often been seen to produce particularly encouraging regrowth in stubborn areas, such as when treating a receding hairline.
This treatment, which is applied directly to the scalp wherever it is needed so is easy to ensure coverage, is often combined with finasteride 1mg; a daily tablet which inhibits the formation of DHT in order to head genetic hair loss off at the root in those diagnosed with this common condition.
Together these two treatments can be incredibly effective in stopping and regrowing thinning hair plus, for those looking for a fully holistic approach, complementary boosters recommended according to each client’s individual needs by their hair loss specialist, can be combined with either or both products to maximise the hair’s potential.
The Belgravia Centre
The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.